Consistent product quality requires a clear understanding of the essence of CGMPs. Experts fear that the message is not always getting through to compounders.
Pharmaceutical compounding recalls the earliest days of medicine making, when the mortar and pestle, and variability, were the rule. Since that time, and the establishment of the United States Pharmacopeia (USP) and FDA in the United States, the field has come a long way.
Read this article in Pharmaceutical Technology's Regulatory Sourcebook October 2020 eBook.
Pharmaceutical Technology
eBook: Regulatory Sourcebook
October 2020
Pages: 46-51
When referring to this article, please cite it as A. Shanley, “Ending ‘Magical Thinking’ in Compounding," Pharmaceutical Technology Regulatory Sourcebook eBook (October 2020).
Legal and Regulatory Perspectives on 3D Printing: Drug Compounding Applications
December 10th 2024This paper explores the legal and regulatory framework around 3D drug printing, particularly for personalized medicine, considering regulatory compliance, business concerns, and intellectual property rights.
Drug Solutions Podcast: Digital Transformation in the Biopharma Industry
October 19th 2023In this episode of the Drug Solutions Podcast, industry experts discuss the challenges and advantages of the digitalization trend in the biopharma industry, with particular emphasis on the impacts to biomanufacturing.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.